Print Page | Sign In
James Q. Del Rosso, DO, FAOCD
Share |

Dr. James Q. Del Rosso, DO, FAOCD, FAAD, was born in Brooklyn, New York, and attended pharmacy school at St. John’s University in Jamaica, New York. He completed a hospital pharmacy residency at Temple University in Philadelphia, PA. Dr. Del Rosso graduated from medical school at Ohio University with honors and then completed his approved dermatology residency at the Atlantic Skin Disease Association in Fort Lauderdale, Florida.

He additionally completed a fellowship approved by the American College of Mohs Surgery in Mohs Micrographic Surgery and Cutaneous Oncology at Ohio State. Dr. Del Rosso is board certified in Dermatology and Mohs Micrographic Surgery and is fully licensed in the State of Nevada.

Dr. Del Rosso is an internationally renowned educator and speaker with several publications in recognized dermatology journals. He is a frequently invited presenter at major dermatology meetings in both the United States and globally, often talking about what is new in therapeutics and drug development. Additionally, he has written and published several articles on a variety of skin diseases including proper care of the skin barrier, acne, rosacea, psoriasis, atopic dermatitis, and eczemas, actinic keratosis, and skin cancers. He is also the co-editor of the textbook, Acne Vulgaris.

He is a past president of the American Acne & Rosacea Society, the American Society for Mohs Surgery, and the American Osteopathic College of Dermatology. He is editor-in-chief of the Journal of Clinical Aesthetic Dermatology since its inception in 2005. He has also authored several recognized publications on guidelines for management of acne, rosacea, atopic dermatitis, psoriasis, and skin cancer.

He founded the Scientific Panel for Antibiotic Use in Dermatology in 2005, with three meetings and scientific publications authored by the group under his direction to guide clinicians on optimal antibiotic use.

Dr. Del Rosso is research director and principal investigator of JDR Dermatology Research, in addition to having his dermatology clinic that is fully dedicated to the care of people with skin disorders or have concerns about their skin. The research center conducts studies for a wide variety of skin conditions, such as acne, rosacea, psoriasis, eczemas, urticaria, actinic keratosis, and skin cancer. Dr. Del Rosso has over 25 years of experience in dermatology research and related publications, and he employs a highly experienced and skilled staff. Dr. Del Rosso is in dermatology practice at Thomas Dermatology in Las Vegas, Nevada. He has been practicing dermatology in the Las Vegas area for 20 years.

Dr. Del Rosso was the recipient of a lifetime achievement award by the American Academy of Dermatology (AAD) in March 2016 for his lifelong commitment to dermatology and his contributions to the field. He now has the distinguished title of Honorary Member with the Academy.

Outside of his professional activities, Dr. Del Rosso is an avid lover of music and sports. He is the proud owner of what can be considered to be a “museum” of sports memorabilia and rock and roll music memorabilia, including a collection of limited edition guitars and vintage guitars. He also attends many concerts, usually sitting in the first row middle section. His motto about attending concerts is admittedly a selfish one: “The concert is being put on specifically for me…I am just nice enough to let everyone else in”. In 2015, Dr. Del Rosso recorded a CD entitled “My Royal Dream by Dr. D and the LL-7”, at the legendary Royal Studios in Memphis Tennessee. The producer and recording engineer of this CD was Lawrence “Boo” Mitchell, who has recorded several major artists, and won a Grammy Award for being the recording engineer for “Uptown Funk” by Bruno Mars, which was also recorded at Royal Studios. Dr. Del Rosso is proud to say he is a good father and a “very cool” grandfather. The loves of his life are his wife Karyn, his daughter Jaclyn, his sister Marilyn and brother-in-law Pat, his stepchildren Chrystyna and Ron, his son-in-law David, and his grandchildren Allyson, Blake, Emily, and Asher. He is also thankful for having had great parents and loves his inner circle of great loyal friends. Dr. Del Rosso is proud and happy to say, “I have no bucket list. I have done everything I have wanted to do and I believe it has always been done well. It is time for the icing on the cake at this point in my life. I do what I enjoy and get great pleasure in giving back through personal generosity and the professional work that I do. My hope is to record another CD with Boo Mitchell. That was the greatest week of my life”.

  

What’s New in the Medicine Chest? A Therapeutic Update

Objectives:

  1. Discuss new developments in management of chronic inflammatory skin disorders such as atopic dermatitis, psoriasis, acne, and rosacea and also infectious disorders (i.e. warts, molluscum)
  2. Explain modes of action related to specific newer therapies that may contribute to therapeutic benefit and/or adverse effects
  3. List specific newer therapeutic agents and their potential advantages as part of the therapeutic armamentarium

Needs: 

  1. New advances in dermatologic treatment
  2. New methods of diagnosis or treatment
  3. Availability of new medication(s) or indication(s)
  4. Development of new technology
  5. Advances in medical knowledge

References:

  1. James Q Del Rosso, DO, Leon Kircik, MD, Tina Lin PharmD, Radhakrishnan Pillai, PhD. “Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.” JCAD, Jan 2019’ 12(1):11-15.
  2. James Q Del Rosso, DO. “What’s New in the Medicine Chest? Monoclonal Antibody Therapies for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management?” JCAD, Feb 2019;12(2): 39-43.
  3. James Q Del Rosso, DO and Leon Kircik, MD. “Topical Cantharidin in the Management of Molluscum Contagiosum: Preliminary Assessment of an Ether-free, Pharmaceutical-grade Formulation.” JCAD, Feb 2019;12(2):11-14.
  4. James Q Del Rosso, DO. “In Focus: Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?” JCAD. July 2017;10(7):28-32.
  5. James Q Del Rosso, DO. “Ingenol Mebutate Topical Gel: A Status Report on Clinical Use Beyond Actinic Keratosis.” JCAD, Nov 2016;9(11): S3-S11.
  6. James Q Del Rosso, DO and Leon Kircik, MD. “The Effect of Calcipotriene-Betamethasone Dipropionate Aerosol Foam versus Vehicle on Target Lesions in Moderate Severity Plaque Psoriasis: Focus on Elbows and Knees.” Journal of Drugs in Dermatology, April 2019;18(4): 327-30.
  7. James Q Del Rosso, DO and Leon Kircik, MD. “Oral Apremilast for the Treatment of Plaque Psoriasis.” J Clin Aesthet Dermatol. 2016;9(9):43-48.
  8. James Q Del Rosso, DO. “In Focus: Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.” JCAD, Sept 2017;10(9): 39-42.

Core Competencies: 2, 3, 6, 7

What Laboratory Tests Are Important to Order?

Objectives:

  1. Discuss new developments in management of chronic inflammatory skin disorders such as atopic dermatitis, psoriasis, acne, and rosacea and also infectious disorders (i.e. warts, molluscum)
  2. Explain modes of action related to specific newer therapies that may contribute to therapeutic benefit and/or adverse effects
  3. List specific newer therapeutic agents and their potential advantages as part of the therapeutic armamentarium

Needs: 

  1. New advances in dermatologic treatment
  2. New methods of diagnosis or treatment
  3. Availability of new medication(s) or indication(s)
  4. Development of new technology
  5. Advances in medical knowledge

References:

  1. James Q Del Rosso, DO, Leon Kircik, MD, Tina Lin PharmD, Radhakrishnan Pillai, PhD. “Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.” JCAD, Jan 2019’ 12(1):11-15.
  2. James Q Del Rosso, DO. “What’s New in the Medicine Chest? Monoclonal Antibody Therapies for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management?” JCAD, Feb 2019;12(2): 39-43.
  3. James Q Del Rosso, DO and Leon Kircik, MD. “Topical Cantharidin in the Management of Molluscum Contagiosum: Preliminary Assessment of an Ether-free, Pharmaceutical-grade Formulation.” JCAD, Feb 2019;12(2):11-14.
  4. James Q Del Rosso, DO. “In Focus: Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?” JCAD. July 2017;10(7):28-32.
  5. James Q Del Rosso, DO. “Ingenol Mebutate Topical Gel: A Status Report on Clinical Use Beyond Actinic Keratosis.” JCAD, Nov 2016;9(11): S3-S11.
  6. James Q Del Rosso, DO and Leon Kircik, MD. “The Effect of Calcipotriene-Betamethasone Dipropionate Aerosol Foam versus Vehicle on Target Lesions in Moderate Severity Plaque Psoriasis: Focus on Elbows and Knees.” Journal of Drugs in Dermatology, April 2019;18(4): 327-30.
  7. James Q Del Rosso, DO and Leon Kircik, MD. “Oral Apremilast for the Treatment of Plaque Psoriasis.” J Clin Aesthet Dermatol. 2016;9(9):43-48.
  8. James Q Del Rosso, DO. “In Focus: Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.” JCAD, Sept 2017;10(9): 39-42.

Core Competencies: 2, 3, 6, 7

Disclosures: Aqua/Almirall, Celgene, Encore, Epi Health, Ferndale, Galderma, Genentech, Leo Pharma, Ortho, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, Taro. Athenex, BioPharma, Botanix, Celgene, Dermira, Epi Health, Foamix, Novan, Dermira, La Roche Posay, Sonoma (Intraderm)

2902 North Baltimore Street | P.O. Box 7525 | Kirksville, Missouri 63501

660-665-2184 | 1-800-449-2623 | 660-627-2623